Feb. 7 at 3:05 PM
Commercial-stage oncology focused bio valuations, analyst revenue estimates & related revenue multiples as of 2/6/26.
$RIGL is off ~30% from its peak last Thanksgiving (after RIGL reported its 2nd meaningful quarterly beat in a row). Tavalisse was approved 4/17/18 yet grew ~50% Q425 v Q424 (and ~70% Q3 v Q3). RIGL now trades at 2.2X FY26 consensus (gross margins = 93%).
$GERN is up 15% YTD. GERN laid off 1/3 of its work force in December. We should get the Myelofibrosis data read in 2H26.
$VSTM reported Q425 sales of
$17.5MM on 2/4/26 v.
$16.5MM consensus. VSTM's multiples are still on the lower end v peers.
$DAWN trades at multiples 2X+ higher than last summer.
$IBRX consensus may or may not have been revised after reporting the meeting with the FDA on the bladder cancer label expansion.
This is not investment advice. We're only sharing our analysis which may or may not be credible.
